We have a promising and diverse pipeline consisting of preclinical, early, mid and late stage products, that focus on cancer treatment for unmet medical need and significant commercial opportunities. Through our active partnership programs and original discovery efforts, we are advancing a broad range of development targets with multiple opportunities for success in different types of cancer.

Our late-stage clinical development efforts are being driven by our experienced team in our U.S. headquarters in New Jersey. We currently have three ongoing clinical programs: 

• An FDA Fast Track-designated treatment for head and neck squamous cell carcinoma (HNSCC) 

• A unique, phase-3 ready intravenously-administered oncolytic virus 

• The most advanced potential first-in-class oral EP4 antagonist in clinical trials

Additionally, our scientists are actively engaged in discovery with pre-clinical assets currently in our pipeline. With our extensive investigational capabilities, we have the flexibility to quickly and aggressively pursue promising avenues of development as they emerge.